¡i©ú³ø±M°T¡j»sÃĤ½¥qTeva Pharmaceutical Industries Ltd.(¥N¸¹TEVA)©P¤TºÙ¡A¹w®Æ¨ä§@»ù400»õ¦¬ÁÊAllergan Plc.(¥N¸¹AGN)ªºl¥ÍÃÄ·~°È¥æ©ö¡A¥iÀH®É§¹¦¨¡A¥uÔ·í§½¼f§å¡C¸Ó¤½¥q¤w©µªø§¹¦¨¥æ©ö´Á¦Ü10¤ë¡A¥H«K¬ü°ê·í§½¦³¥R¤À®É¶¡§@¤ÏÃbÂ_¼f§å¡C
¬O¶µ¥æ©ö¦©ó¤@¦~«e¤½¥¬¡A¥»¨Ó¹wq©ó¤W¤ë§¹¦¨¡A¦ý¥Ñ©ó¨â®a¤½¥q¶·²æ°â¦hºØÃĪ«Åv¯q¥Hº¡¨¬¤ÏÃbÂ_n¨D¡A¨ä¼Æ¶q¸û¹w´Á¬°¦h¡A¥æ©ö»Ý®É¥ç¦]¦Ó¸ûªø¡C
Teva¦æ¬FÁ`µôErez Vigodman¦b¤@Ó¤ÀªR®v·|ij¤W»¡¡J¡u§Ú̲{®É¹w´Á¡A¦¬Áʦ¹¤@l¥ÍÃĪ«·~°Èªº¥æ©ö·|ÀH®É§¹¦¨¡C¡v
¥æ©ö¶·¥ý³q¹L¬ü°êÁp¨¹°Ó·~©eû·|(FTC)ªº¼f®Ö¤è¯à§@¹ê¡A¨â¤½¥qªí¥Ü¡A¹w®Æ·í§½ÀH®É·|§@¥X§åã¡CVigodman»¡¡A¤@¥¹§å¥X¡A¥u»Ý¤Q¤Ñ®É¶¡«K¥i§¹¦¨¥æ©ö¡C
FTC¤@¦Wµo¨¥¤H©Ú´N¦¹¨Æ§@¥Xµû½×¡C
Teva ªÑ»ù©P¤T¦¬³ø54.46¬ü¤¸¡A¤É2¬ü¤¸¡A©Î3.81%¡CAllergan«h¦¬241.17¬ü¤¸¡A¤É1.47¬ü¤¸¡A©Î0.61%¡C
Allergan¦P®É¦b©P¤T¤@¥÷§e¥æ·í§½¤å¥ó¤¤ªí¥Ü¡A¨â®a¤½¥q¤wקï¨ä¾P°â¨óij¡A©µªø¥æ©ö´Á¤TÓ¤ë¦Ü¤µ¦~10¤ë¤î¡C¥Ñ©ó¼f®Öª½¦Ü7¤ë¤´¥¼¦³µ²ªG¡A¤£¯à»°¤Îìq´Áªº¥i¯à©Ê¤j¼W¡C
¤å¥ó¥ç³zÅS¡AAllergan²{®Ép¹º¨ú®ø¦b¥æ©ö¤¤²æ°â¨âºØÃĪ«¡JActonel¤ÎCarafate¡C
Teva«h¦P·N±N¬Y´XÃþÃĪ«°â¤©²Ä¤TªÌ¡A¥H¨D³q¹L¼f§å¡A6¤ë®É¡A¸Ó¤½¥q¤½¥¬¦V¿D¬wªºMayne Pharma Group Ltd.²æ°â»ùÈ6.52»õ¬ü¤¸ªºÃĪ«Åv¯q¡C
Teva©P¤Tªº¤ÀªR®v·|ij¤Wªí¥Ü¡A¹w´Á2016¤º·|°â¥X¬ù29»õ¬ü¤¸ªº¸ê²£¡C¨Ã¹w®ÆAllerganªºl¥ÍÃÄ·~°È©ó2017¦~¤º¬°¤½¥q±a¨Ó19»õ¬ü¤¸ªº²b¼W¯q¡CTeva¹w®Æ¡A2016¦~Á`¦¬¤J·|¦b220¦Ü225»õ¬ü¤¸¶¡¡A½Õ¾ã«á¬Õ§Q¤¶¥G5.20»P5.40¬ü¤¸¤§¶¡¤@ªÑ¡C